Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May 30;18(5):261-4.
doi: 10.1016/j.rpor.2013.04.034.

3D conformal hypofractionated radical radiotherapy in early glottic cancer

Ana Cristina Amado  1 , Laurentiu Bujor  1 , Isabel Monteiro Grillo  2
Affiliations
Review

3D conformal hypofractionated radical radiotherapy in early glottic cancer

Ana Cristina Amado et al. Rep Pract Oncol Radiother. .

Abstract

Aim: The purpose of this study was to evaluate acute and late toxicity and the locoregional control in patients treated with hypofractionated radical radiotherapy 2.25 Gy/fraction/day for early glottic carcinoma.

Materials and methods: A retrospective analysis was performed of 27 patients, stage T1-T2 N0 glottic squamous cell carcinoma, that underwent radical RT from April 2008 to October 2011. The mean age was 64.6 years (range 36-81). Seventeen patients were staged T1a, 3 patients T1b and 7 patients T2. All patients were 3D planned and treated in a 6 MV LINAC, 2.25 Gy/fraction/5 days per week, to a total dose between 63 Gy and 67.5 Gy. Biological Effective Dose (BED (α/β = 10)) ranged from 77.18 Gy to 82.69 Gy and EQD2 from 64.31 Gy to 68.91 Gy. Patients were evaluated in periodic follow-up. Toxicity was evaluated according to RTOG Toxicities Scales.

Results: With a median follow-time of 24.7 months (range 3.6-44.2 months), no evidence of locoregional recurrence was observed. The treatment was well tolerated and no unscheduled interruptions in treatments for toxicity were documented, with the median overall treatment time of 41 days (range 38-48). Only grades 1 and 2 acute toxicity were observed and no evidence of severe late toxicity.

Conclusion: The authors believe that this moderately hypofractionated scheme can provide a good locoregional control for T1-T2 glottic carcinomas with no increase of toxicity. As the limitation of this work is the reduced number of patients and the lack of long term follow-up, the authors hope to update this retrospective study in the future in order to improve the power of the results.

Keywords: Early glottic cancer; Hypofractionation; Larynx; T1–T2.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hansen E., Roach M. Handbook of evidence-based radiation oncology. second ed. Springer; New York Heidelberg Dordrecht London: 2010. Larynx and hypopharynx cancer; pp. 145–162.
    1. Chao K., Perez C., Brady L. Radiation oncology management decisions. third ed. Lippincott Williams & Wilkins; Philadelphia: 2011. Larynx; pp. 285–298.
    1. Abraham J., Gulley J., Allegra C. The Bethesda handbook of clinical oncology. third ed. Lippincott Williams & Wilkins; Philadelphia: 2010. Head and neck; pp. 3–21.
    1. Fein D.A., Mendenhall W.M., Parsons J.T. T1–T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int J Radiat Oncol Biol Phys. 1993;25(4):605–611. - PubMed
    1. Mendenhall W.M., Parsons J.T., Stringer S.P. Management of Tis, T1, and T2 squamous cell carcinoma of the glottic larynx. Am J Otolaryngol. 1994;15(4):250–257. - PubMed